BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 21491451)

  • 1. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
    Rawat MK; Jain A; Singh S
    J Pharm Sci; 2011 Jun; 100(6):2406-17. PubMed ID: 21491451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
    Rawat MK; Jain A; Singh S
    J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
    Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
    Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of a novel lipohydrogel nanocarrier: repaglinide as a lipophilic model drug.
    Ebrahimi HA; Javadzadeh Y; Hamidi M; Barzegar Jalali M
    J Pharm Pharmacol; 2016 Apr; 68(4):450-8. PubMed ID: 27114047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method.
    Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
    Curr Drug Deliv; 2010 Jan; 7(1):44-50. PubMed ID: 20044909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.
    Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B
    Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery.
    Date AA; Vador N; Jagtap A; Nagarsenker MS
    Nanotechnology; 2011 Jul; 22(27):275102. PubMed ID: 21606564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization and invivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles.
    Dhana Lekshmi UM; Poovi G; Kishore N; Reddy PN
    Int J Pharm; 2010 Aug; 396(1-2):194-203. PubMed ID: 20600729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of oral absorption of oxyresveratrol using lipid based nanoparticles.
    Sangsen Y; Wiwattanawongsa K; Likhitwitayawuid K; Sritularak B; Wiwattanapatapee R
    Colloids Surf B Biointerfaces; 2015 Jul; 131():182-90. PubMed ID: 25988282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide.
    Gonçalves LM; Maestrelli F; Di Cesare Mannelli L; Ghelardini C; Almeida AJ; Mura P
    Eur J Pharm Biopharm; 2016 May; 102():41-50. PubMed ID: 26925503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide-Solid Lipid Nanoparticles in Chitosan Patches for Transdermal Application: Box-Behnken Design, Characterization, and In Vivo Evaluation.
    Ali HSM; Namazi N; Elbadawy HM; El-Sayed AAA; Ahmed SA; Bafail R; Almikhlafi MA; Alahmadi YM
    Int J Nanomedicine; 2024; 19():209-230. PubMed ID: 38223883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Eur J Pharm Biopharm; 2017 Jan; 110():47-57. PubMed ID: 27810472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
    Jain S; Saraf S
    J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Pharmacodynamics of Curcumin-Loaded Solid Lipid Nanoparticles in the Management of Streptozotocin-Induced Diabetes Mellitus: Application of Central Composite Design.
    Sharma JB; Bhatt S; Saini V; Kumar M
    Assay Drug Dev Technol; 2021; 19(4):262-279. PubMed ID: 34000202
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
    Thirupathi G; Swetha E; Narendar D
    Drug Res (Stuttg); 2017 Mar; 67(3):163-169. PubMed ID: 27992936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
    Garg A; Singh S
    Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery.
    Dong Z; Xie S; Zhu L; Wang Y; Wang X; Zhou W
    Drug Deliv; 2011 Aug; 18(6):441-50. PubMed ID: 21554156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles.
    Lingling G; Yuan Z; Weigen L
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1325-33. PubMed ID: 26821124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
    Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
    AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.